Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed FCF Margin for 6 consecutive years, with 34.27% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 456783427.0% to 34.27% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 128.02% through Dec 2025, up 36499090.0% year-over-year, with the annual reading at 128.02% for FY2025, 36499090.0% up from the prior year.
  • FCF Margin for Q4 2025 was 34.27% at 4D Molecular Therapeutics, up from 51563.33% in the prior quarter.
  • The five-year high for FCF Margin was 142505.26% in Q4 2023, with the low at 4567800.0% in Q4 2024.
  • Average FCF Margin over 5 years is 343069.35%, with a median of 9663.66% recorded in 2023.
  • The sharpest move saw FCF Margin crashed -471030526bps in 2024, then skyrocketed 456783427bps in 2025.
  • Over 5 years, FCF Margin stood at 21761.96% in 2021, then surged by 92bps to 1832.72% in 2022, then surged by 7876bps to 142505.26% in 2023, then tumbled by -3305bps to 4567800.0% in 2024, then skyrocketed by 100bps to 34.27% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 34.27%, 51563.33%, and 292893.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.